James Treco - 08 May 2023 Form 4 Insider Report for Tonix Pharmaceuticals Holding Corp. (TNXP)

Role
Director
Signature
/s/ Jessica Morris, Attorney-in-Fact
Issuer symbol
TNXP
Transactions as of
08 May 2023
Transactions value $
$0
Form type
4
Filing time
10 May 2023, 17:01:11 UTC
Previous filing
11 May 2022
Next filing
24 May 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TNXP Stock Option Award $0 +60,000 $0 60,000 08 May 2023 Common Stock 60,000 $0.509 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan and vests on the earlier of the one year anniversary of the grant date or the Issuer's 2024 Annual Meeting of Stockholders.
F2 Does not reflect a 1-for-6.25 reverse stock split of the Issuer's common stock effective May 10, 2023.